Latest On Eagle Pharmaceuticals, Inc (EGRX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-10 02:20 EST | News | Eagle Pharmaceuticals, Inc. (EGRX) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-09 12:39 EST | News | Eagle Pharmaceuticals Non-GAAP EPS of $1.26 beats by $0.27, revenue of $66.3M beats by $2.97M | N/A | |
| 2023-05-08 23:22 EST | News | Eagle Pharmaceuticals Q1 2023 Earnings Preview | N/A | |
| 2023-04-05 21:57 EST | News | Eagle Pharma reaches settlement agreement with Dr. Reddy’s Lab | N/A | |
| 2023-03-13 12:59 EST | News | Eagle Pharmaceuticals Non-GAAP EPS of $1.11 beats by $0.28, revenue of $60.7M misses by $3.56M | N/A | |
About Eagle Pharmaceuticals, Inc (EGRX):
Eagle Pharmaceuticals, Inc., a biotechnology pharmaceutical company, focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance read more... oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
General
- Name Eagle Pharmaceuticals, Inc
- Symbol EGRX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 106
- Fiscal Year EndDecember
- IPO Date2014-02-12
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.eagleus.com
Valuation
- Trailing PE 51.8
- Forward PE 14.12
- Price/Sales (Trailing 12 Mt.) 3.31
- Price/Book (Most Recent Quarter) 3.21
- Enterprise Value Revenue 2.82
- Enterprise Value EBITDA 17.64
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $3.28
- Next Year EPS Estimate $4.02
- Next Quarter EPS Estimate $0.39
- Profit Margin 6%
- Operating Margin 18%
- Return on Assets 8%
- Return on Equity 7%
- Revenue 187.8 million
- Earnings Per Share $0.87
- Revenue Per Share $13.93
- Gross Profit 142.34 million
- Quarterly Earnings Growth 3.4%
Highlights
- Market Capitalization 595.7 million
- EBITDA 36.49 million
- PE Ratio 5.59
- PEG Ratio 0.91
- Analyst Target Price $48
- Book Value Per Share $14.25
Share Statistics
- Shares Outstanding 13.22 million
- Shares Float 10.86 million
- % Held by Insiders 2224%
- % Held by Institutions 99.11%
- Shares Short 1.4 million
- Shares Short Prior Month 1.3 million
- Short Ratio 11.9
- Short % of Float 17%
- Short % of Shares Outstanding 11%
Technicals
- Beta 0.62
- 52 Week High $56.16
- 52 Week Low $36.31
- 50 Day Moving Average 46.02
- 200 Day Moving Average 45.68
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Eagle Pharmaceuticals, Inc (EGRX) Dividend Calendar:
Eagle Pharmaceuticals, Inc (EGRX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Eagle Pharmaceuticals, Inc (EGRX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | 4.83 million | N/A | 9.43 million | 11.31 million |
| Income Before Tax | N/A | 8.93 million | N/A | -3.01 million | 3.36 million |
| Selling General Administrative | N/A | 17.7 million | N/A | 24.76 million | 22.46 million |
| Gross Profit | N/A | 37.94 million | N/A | 38.22 million | 36.67 million |
| Ebit | N/A | 10.79 million | N/A | -981000 | 2.9 million |
| Operating Income | N/A | 15.42 million | N/A | 4.04 million | 2.9 million |
| Income Tax Expense | 3.33 million | N/A | 5.63 million | N/A | 2.35 million |
| Total Revenue | N/A | 49.93 million | N/A | 46.02 million | 48.26 million |
| Cost of Revenue | N/A | 11.99 million | N/A | 7.8 million | 11.59 million |
| Total Other Income Expense Net | N/A | -6.05 million | N/A | -6.5 million | 461000 |
| Net Income From Continuing Operations | N/A | 7.06 million | N/A | -2.87 million | 1.01 million |
| Net Income Applicable to Common Shares | 8.06 million | N/A | -256000 | -2.87 million | 1.01 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -201000 | N/A | N/A | N/A | N/A |
| Change to Liabilities | N/A | 3.95 million | N/A | -5.77 million | -6.06 million |
| Total Cash Flow from Investing Activities | N/A | 96000 | -17.97 million | -130000 | -304000 |
| Net Borrowings | N/A | -111 million | N/A | -1000000 | -1.25 million |
| Total Cash Flow from Financial Activities | -23.96 million | N/A | 107.06 million | -4.11 million | -1.23 million |
| Change to Operating Activities | N/A | 4.64 million | N/A | -2.92 million | -7.61 million |
| Change in Cash | -18.53 million | N/A | 92.24 million | -7.44 million | 9.08 million |
| Total Cash from Operating Activities | 5.63 million | 20.95 million | 3.16 million | -3.2 million | 10.61 million |
| Depreciation | 1.37 million | N/A | 472000 | 1.28 million | 582000 |
| Other Cash Flow from Investing Activities | N/A | N/A | -17.5 million | N/A | N/A |
| Change to Inventory | 1.31 million | N/A | N/A | 682000 | 4.35 million |
| Change to Account Receivables | -5.42 million | N/A | N/A | -3.19 million | 15.53 million |
| Other Cash Flow from Financing Activities | N/A | N/A | -1.28 million | -326000 | N/A |
| Change to Net Income | N/A | 3.12 million | N/A | 5.51 million | 6.13 million |
| Capital Expenditures | 201000 | N/A | 472000 | 130000 | 304000 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | 75.37 million | N/A | 180.11 million | 75.38 million |
| Total Stockholder Equity | N/A | 172.79 million | N/A | 181.83 million | 179.17 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | N/A | 248.16 million | N/A | 361.94 million | 254.55 million |
| Common Stock | 17000 | N/A | 17000 | 17000 | 17000 |
| Other Current Assets | N/A | 3.67 million | N/A | 691000 | 8.57 million |
| Retained Earnings | 84.49 million | 76.43 million | 69.37 million | 69.63 million | 72.5 million |
| Other Liabilities | N/A | N/A | 3.36 million | N/A | N/A |
| Other Assets | 32.39 million | N/A | 32.16 million | 29.29 million | 13.86 million |
| Cash | N/A | 89.68 million | N/A | 202.02 million | 109.78 million |
| Total Current Liabilities | 38.09 million | 45.51 million | N/A | 145.88 million | 38.82 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 2.08 million | N/A | 2.12 million | 2.42 million | 5.92 million |
| Total Current Assets | 166.07 million | 163.8 million | N/A | 275.57 million | 179.45 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 133.35 million | N/A | 129.97 million | N/A | 123.85 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | 27.02 million | N/A | 30.78 million | 33.56 million |
| Inventory | 8.08 million | 6.59 million | N/A | 8.43 million | 6.57 million |
| Accounts Payable | 6.27 million | 13.07 million | N/A | 9.76 million | 5.46 million |
Eagle Pharmaceuticals, Inc (EGRX) Chart:
Eagle Pharmaceuticals, Inc (EGRX) News:
Below you will find a list of latest news for Eagle Pharmaceuticals, Inc (EGRX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Eagle Pharmaceuticals, Inc (EGRX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest EGRX Trades:
Eagle Pharmaceuticals, Inc (EGRX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-02 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-02 | 8-K (Current report) | |
| 2020-11-02 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-11-02 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-01 | 8-K (Current report) | |
| 2020-09-28 | 8-K (Current report) | |
| 2020-09-24 | 8-K (Current report) | |
| 2020-09-23 | 8-K (Current report) | |
| 2020-09-14 | 8-K (Current report) | |
| 2020-09-10 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-07-16 | 8-K (Current report) | |
| 2020-07-09 | 8-K (Current report) | |
| 2020-06-29 | 8-K (Current report) | |
| 2020-06-29 | 8-K (Current report) | |
| 2020-06-01 | 8-K (Current report) | |
| 2020-05-22 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-05-19 | 8-K (Current report) | |
Eagle Pharmaceuticals, Inc (EGRX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eagle Pharmaceuticals, Inc (EGRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2224%
Institutional Ownership: 9911%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-01-05 | Scott Tarriff | CEO | Buy | 58,300.00 | 1,558,502.00 | | ||
| 2020-01-05 | Pete A. Meyers | Chief Financial Officer | Buy | 19,500.00 | 45,900.00 | | ||
| 2020-01-05 | Adrian Hepner | EVP and Chief Medical Officer | Buy | 24,000.00 | 51,229.00 | | ||
| 2020-01-05 | David Pernock | Pres. & Chief Comm. Officer | Buy | 21,500.00 | 52,508.00 | | ||
| 2019-10-25 | Executive Capital LP Hudson | Director | Sell | 15,437.00 | 63.57 | 981,302.30 | 732,777.00 | |
| 2019-10-24 | Executive Capital LP Hudson | Director | Sell | 1,494.00 | 62.53 | 93,412.50 | 748,214.00 | |
| 2019-10-23 | Executive Capital LP Hudson | Director | Sell | 200.00 | 62.58 | 12,516.00 | 749,708.00 | |
| 2019-10-22 | Executive Capital LP Hudson | Director | Sell | 6,567.00 | 62.68 | 411,617.59 | 749,908.00 | |
| 2019-10-21 | Executive Capital LP Hudson | Director | Sell | 3,849.00 | 62.56 | 240,790.75 | 756,475.00 | |
| 2019-10-18 | Executive Capital LP Hudson | Director | Sell | 1,600.00 | 62.61 | 100,174.08 | 760,324.00 | |
| 2019-10-17 | Executive Capital LP Hudson | Director | Sell | 13,842.00 | 62.58 | 866,196.37 | 761,924.00 | |
| 2019-10-16 | Executive Capital LP Hudson | Director | Sell | 102.00 | 62.50 | 6,375.00 | 775,766.00 | |
| 2019-10-15 | Executive Capital LP Hudson | Director | Sell | 3,909.00 | 62.63 | 244,835.92 | 775,868.00 | |
| 2019-10-11 | Executive Capital LP Hudson | Director | Sell | 16,300.00 | 60.39 | 984,418.94 | 779,777.00 | |
| 2019-10-10 | Executive Capital LP Hudson | Director | Sell | 7,829.00 | 60.16 | 471,002.03 | 796,077.00 | |
| 2019-10-08 | Executive Capital LP Hudson | Director | Sell | 1,558.00 | 60.03 | 93,519.73 | 803,906.00 | |
| 2019-10-07 | Executive Capital LP Hudson | Director | Sell | 4,901.00 | 60.11 | 294,599.60 | 805,464.00 | |
| 2019-09-17 | Executive Capital LP Hudson | Director | Sell | 100.00 | 60.00 | 6,000.00 | 810,365.00 | |
| 2019-09-12 | Executive Capital LP Hudson | Director | Sell | 200.00 | 60.07 | 12,014.00 | 810,465.00 | |
| 2019-09-11 | Executive Capital LP Hudson | Director | Sell | 1,112.00 | 60.06 | 66,784.94 | 810,665.00 | |